Top 10 medtech deals in the first half of 2026

Boston Scientific, Medtronic and Stryker were among the companies to ink deals to move into markets that are expanding quickly.

By Nick Paul Taylor • July 6, 2026

Guardant’s Shield colon cancer blood test snags UnitedHealth coverage

One analyst called the insurer’s decision a “watershed moment” for liquid biopsy-based cancer screening and for the category of blood-based cancer testing.

By Susan Kelly • July 2, 2026

Explore the Trendline➔

Top 5 stories from MedTech Dive

From the effects of layoffs at the Food and Drug Administration and President Donald Trump’s tariff policies to the top medtech trends of 2026, here is a collection of top stories from MedTech Dive.

By MedTech Dive staff

Agilent finalizes Biocare Medical takeover

The acquisition strengthens Agilent’s presence in areas including cancer and infectious disease diagnostic and research markets.

By Nick Paul Taylor • June 26, 2026

Labcorp rolls out colorectal cancer screening test nationwide

The Geneoscopy test competes with Exact Sciences’ Cologuard for the U.S. colorectal cancer screening market.

By Nick Paul Taylor • June 25, 2026

Danaher closes $9.9B Masimo buyout

CEO Rainer Blair said Danaher has the money and “leadership bandwidth” to strike further deals across any of its three business areas.

By Nick Paul Taylor • June 11, 2026

Olympus’ Keith Boettiger on robotic GI surgery push

Keith Boettiger, head of Olympus’ gastrointestinal solutions division, delves into the endoscopy leader’s endoluminal robotics strategy.

By Susan Kelly • June 5, 2026

At ASCO, Grail points to positive signals in MCED data

Grail executives were upbeat on study results for the Galleri multi-cancer early detection test, while ASCO said more evidence is needed before it is incorporated into screening guidelines.

By Susan Kelly • June 2, 2026

California attorney general sues over 23andMe data breach

The attorney general said the civil penalties could add up to “multiple millions” if the suit is successful.

By Elise Reuter • May 29, 2026

Natera’s Solomon Moshkevich on how MRD testing pinpoints cancer recurrence

Molecular residual disease testing could one day be as ubiquitous as a CT scan, says Natera’s president of clinical diagnostics.

By Susan Kelly • May 29, 2026

Guardant wins FDA approval for updated liquid biopsy

The company could secure a higher price for the new test than for its older, narrower product, Wall Street analysts said.

By Nick Paul Taylor • May 21, 2026

Natera wins FDA approval for companion diagnostic

The test will enable physicians to assess if post-surgery cancer patients need to receive treatment to minimize the risk of recurrence.

By Nick Paul Taylor • May 18, 2026

Labcorp expands Epic pact to make full test menu available on Aura

The Labcorp agreement continues the expansion of Aura, which gives healthcare providers access to tests from companies including Quest Diagnostics.

By Nick Paul Taylor • May 14, 2026

Roche to acquire digital pathology firm PathAI for up to $1.05B

Roche plans to offer PathAI’s tools as part of an effort to improve cancer diagnosis and tailored treatment.

By Elise Reuter • May 7, 2026

Top medtech executive moves in 2026

Medtech companies have been busy reshaping their C-suites and leadership teams throughout the year. For some, it’s an effort to revamp their businesses. Read MedTech Dive’s roundup for all the details.

By MedTech Dive Staff • Updated Sept. 23, 2026

Thermo Fisher inks $1.1B deal to sell microbiology unit to Astorg

The private equity group plans to accelerate growth of the acquired business, including by empowering it to engage in M&A.

By Nick Paul Taylor • April 28, 2026

With ultrasound on a chip, Butterfly Network aims for global reach

Butterfly, which makes handheld imaging machines, hopes to make the technology accessible to more patients with its pricing and AI features.

By Elise Reuter • April 27, 2026

Medtronic closes $585M purchase of CathWorks

The deal is the second tuck-in acquisition this year for Medtronic, which has signaled its intent to pursue more M&A in its core business lines.

By Susan Kelly • April 20, 2026

Siemens plans shareholder vote on Siemens Healthineers spinoff

The German parent, which is giving up its majority stake in Siemens Healthineers, said preparations for the transaction are progressing toward a vote at its February annual meeting.

By Susan Kelly • April 17, 2026

Abbott lowers earnings forecast after $21B Exact Sciences buy

CEO Robert Ford said the companies are a good cultural fit and he expects demand for Exact’s colon cancer screening test to increase.

By Elise Reuter • April 16, 2026

Hologic CEO Steve MacMillan to retire after go-private deal

The $18.3 billion acquisition by Blackstone and TPG is expected to close Tuesday. 

By Elise Reuter • April 6, 2026

Labcorp closes purchase of New York pathology reference lab assets

The deal, which will see Labcorp run 12 patient service centers, is part of the company’s ongoing efforts to expand through acquisitions.

By Nick Paul Taylor • March 23, 2026

Abbott to close $21B Exact Sciences acquisition Monday

Abbott said it has received all regulatory clearances necessary to buy the cancer screening firm.

By Elise Reuter • March 20, 2026

Grail CEO Bob Ragusa to retire

Josh Ofman, company president, will step into the top job. Guggenheim Securities analysts said the leadership change “has been in development for some time and is unrelated to the NHS trial readout."

By Nick Paul Taylor • March 16, 2026

Genetic tests come under scrutiny in Trump administration’s fraud crackdown

As the Centers for Medicare and Medicaid Services calls for public feedback on how to stop lab test fraud, experts say a tailored regulatory strategy will be key to avoid stifling innovation.

By Susan Kelly • March 12, 2026

Agilent to buy Biocare Medical for $950M

Biocare’s strong growth in immunohistochemistry is expected to strengthen Agilent’s ability to develop new in vitro diagnostic antibodies.

By Susan Kelly • March 9, 2026